
浏览全部资源
扫码关注微信
1.广州开发区医院药学部,广州 510730
2.中山大学孙逸仙纪念医院药学部,广州 510120
主管药师。研究方向:临床药学。E-mail:442124819@qq.com
主管药师,硕士。研究方向:临床药学。电话:020-81332355。E-mail:13826285816@139.com
收稿日期:2023-08-24,
修回日期:2024-03-18,
录用日期:2024-03-18,
纸质出版日期:2024-04-15
移动端阅览
刘晓平,林小鲁,李剑芳.1例艾沙康唑致患者全血细胞减少的病例分析[J].中国药房,2024,35(07):881-885.
LIU Xiaoping,LIN Xiaolu,LI Jianfang.Case analysis of a patient with isavuconazonium-caused pancytopenia[J].ZHONGGUO YAOFANG,2024,35(07):881-885.
刘晓平,林小鲁,李剑芳.1例艾沙康唑致患者全血细胞减少的病例分析[J].中国药房,2024,35(07):881-885. DOI: 10.6039/j.issn.1001-0408.2024.07.20.
LIU Xiaoping,LIN Xiaolu,LI Jianfang.Case analysis of a patient with isavuconazonium-caused pancytopenia[J].ZHONGGUO YAOFANG,2024,35(07):881-885. DOI: 10.6039/j.issn.1001-0408.2024.07.20.
目的
2
正确识别和应对艾沙康唑引起的全血细胞减少的不良反应,为该药的安全使用提供参考。
方法
2
临床药师通过参与1例严重感染合并肾功能不全的患者使用艾沙康唑后出现全血细胞减少的病例分析,筛查患者住院期间所用药物,并结合药物的半衰期和相关文献,评估了该不良反应与艾沙康唑的关系及可能的发生机制。
结果与结论
2
患者全血细胞减少与艾沙康唑的关系评估为“可能相关”。使用艾沙康唑时应提高警惕,避免同时联用相同机制或有潜在相互作用的药物。如疗程大于2周或用药前血液系统异常或合并肝肾功能损害或需要联合使用相同机制的药物者,可考虑增加血常规监测频率。
OBJECTIVE
2
To correctly identify and deal with the adverse drug reaction as pancytopenia caused by isavuconazonium and to provide reference for the safe use of isavuconazonium.
METHODS
2
Clinical pharmacists analyzed a case of severe infection and renal insufficiency who experienced pancytopenia after using isavuconazonium. Clinical pharmacists screened the drugs used during hospitalization and evaluated the relationship between this adverse drug reaction and isavuconazonium, as well as the possible mechanisms, based on the half-life of the drugs and relevant literature.
RESULTS &CONCLUSIONS
2
The relationship between pancytopenia and isavuconazonium was assessed as “possibly related”. When using isavuconazonium, attention should be paid to avoiding the combination of drugs with the same mechanism or potential interaction. For patients who have a course of treatment for more than 2 weeks, have hematological abnormalities or complicated with liver and renal insufficiency, or should use it combined with other drug with same mechanism, it may be considered to increase the frequency of blood routine monitoring.
MCCORMACK P L . Isavuconazonium:first global approval [J ] . Drugs , 2015 , 75 ( 7 ): 817 - 822 .
KULLBERG B J , VISCOLI C , PAPPAS P G , et al . Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections:the ACTIVE trial [J ] . Clin Infect Dis , 2019 , 68 ( 12 ): 1981 - 1989 .
刘文 , 吴侠 , 李峰敏 , 等 . 全血细胞减少的病因诊断及治疗 [J ] . 中国全科医学 , 2011 , 14 ( 17 ): 1961 - 1963 .
LIU W , WU X , LI F M , et al . Etiological diagnosis and treatment of pancytopenia [J ] . Chin Gen Pract , 2011 , 14 ( 17 ): 1961 - 1963 .
宋婷婷 , 冯婧劼 , 马荣 . 抗真菌药物艾沙康唑研究进展 [J ] . 中国新药杂志 , 2015 , 24 ( 3 ): 288 - 297 .
SONG T T , FENG J J , MA R . Progress in research of isavuconazole, an antifungal agent [J ] . Chin J N Drugs , 2015 , 24 ( 3 ): 288 - 297 .
陈欣 , 林韧 . 艾沙康唑临床应用专家共识: 2023版 [J ] . 临床血液学杂志 , 2023 , 36 ( 5 ): 295 - 302 .
CHEN X , LIN R . Consensus recommendations for the clinical application of isavuconazole:2023 edition [J ] . J Clin Hematol , 2023 , 36 ( 5 ): 295 - 302 .
VILLANUEVA A , GOTUZZO E , ARATHOON E G , et al . A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis [J ] . Am J Med , 2002 , 113 ( 4 ): 294 - 299 .
MORA-DUARTE J , BETTS R , ROTSTEIN C , et al . Comparison of caspofungin and amphotericin B for invasive candidiasis [J ] . N Engl J Med , 2002 , 347 ( 25 ): 2020 - 2029 .
MAERTENS J , RAAD I , PETRIKKOS G , et al . Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy [J ] . Clin Infect Dis , 2004 , 39 ( 11 ): 1563 - 1571 .
邓艳辉 , 许静 , 汪燕 . 注射用兰索拉唑联合美罗培南致严重血小板减少症1例 [J ] . 中国新药与临床杂志 , 2017 , 36 ( 1 ): 56 - 58 .
DENG Y H , XU J , WANG Y . One case of serious thrombocytopenia induced by lansoprazole and meropenem for injection [J ] . Chin J N Drugs Clin Remedies , 2017 , 36 ( 1 ): 56 - 58 .
叶婷 , 杜俊龙 , 陈丹 , 等 . 70例美罗培南不良反应文献分析 [J ] . 中国药物应用与监测 , 2022 , 19 ( 5 ): 313 - 317 .
YE T , DU J L , CHEN D , et al . Literature analysis of 70 cases of adverse drug reactions induced by meropenem [J ] . Chin J Drug Appl Monit , 2022 , 19 ( 5 ): 313 - 317 .
张岩岩 , 朱婉 , 张静萍 , 等 . 利奈唑胺致乳酸酸中毒及全血细胞减少1例报道及50例文献复习 [J ] . 中国感染与化疗杂志 , 2017 , 17 ( 4 ): 365 - 370 .
ZHANG Y Y , ZHU W , ZHANG J P , et al . Linezolid-induced lactic acidosis and pancytopenia:one case report and literature review of 50 cases [J ] . Chin J Infect Chemother , 2017 , 17 ( 4 ): 365 - 370 .
高举 , 罗春华 . 自身免疫性血小板减少性紫癜的发病机制及诊治进展 [J ] . 中国实用儿科杂志 , 2003 , 18 ( 2 ): 77 - 79 .
GAO J , LUO C H . Progress in pathogenesis,diagnosis and treatment of autoimmune thrombocytopenic purpura [J ] . Chin J Pract Pediatr , 2003 , 18 ( 2 ): 77 - 79 .
BERNSTEIN W B , TROTTA R F , RECTOR J T , et al . Mechanisms for linezolid-induced anemia and thrombocytopenia [J ] . Ann Pharmacother , 2003 , 37 ( 4 ): 517 - 520 .
国家食品药品监督管理局药品安全监管司 , 国家药品不良反应监测中心 , 药品不良反应报告和监测工作手册 [M ] . 北京 : 国家药品不良反应监测中心 , 2012 : 49 - 51 .
State Food and Drug Administration Drug Safety Supervision Department , National Adverse Drug Reaction Monitoring Center . Manual on reporting and monitoring of adverse drug reactions [M ] . Beijing : National Adverse Drug Reaction Monitoring Center , 2012 : 49 - 51 .
杨焕芝 , 宋沧桑 , 李兴德 , 等 . 替加环素致全血细胞减少不良反应1例 [J ] . 中国医院药学杂志 , 2015 , 35 ( 3 ): 277 - 278 .
YANG H Z , SONG C S , LI X D , et al . A case of adverse reaction of pancytopenia caused by tigecycline [J ] . Chin J Hosp Pharm , 2015 , 35 ( 3 ): 277 - 278 .
李淑杰 . 伏立康唑致骨髓抑制一例 [J ] . 中华全科医师杂志 , 2008 , 7 ( 10 ): 661 .
LI S J . A case of bone marrow suppression caused by voriconazole [J ] . Chin J Gen Pract , 2008 , 7 ( 10 ): 661 .
0
浏览量
32
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
公网安备50010302001817